ReviewJournal of atherosclerosis and thrombosis2023
Lipoproteins, Cholesterol, and Atherosclerotic Cardiovascular Disease in East Asians and Europeans.
Review in Journal of atherosclerosis and thrombosis, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 30 citations in OpenAlex.
- An Elevated Serum Apolipoprotein C-III Concentration is Associated with the Risk of Coronary Heart Disease in a Japanese General Population. The Hidaka Cohort Study.Journal of atherosclerosis and thrombosis · 2026Article
- Oral Semaglutide Further Reduced LDL Cholesterol in a Patient with Familial Hypercholesterolemia Treated with Statins, Ezetimibe, and Evolocumab.Internal medicine (Tokyo, Japan) · 2026Article
- A narrative review of impacts of apolipoproteins on atherosclerotic coronary plaques.NPJ cardiovascular health · 2026Review
- Concordance of genetic determinants of acute coronary artery disease between European and Chinese populations.GigaScience · 2026Article
- Sex- and Ethnic-Specific Associations of Serum Lipids with Risk of 12 Cancers: Findings from 506,381 Adults in Two Large Cohorts.Antioxidants (Basel, Switzerland) · 2025Article
- Contrasting associations of blood lipids with risk of myocardial infarction in Chinese and European adults.European heart journal open · 2025Article
- The Effect of Lipid-Lowering Therapy on Coronary Artery Plaque in East Asia Population.JACC. Asia · 2025Article
- Metabolic diseases in the East Asian populations.Nature reviews. Gastroenterology & hepatology · 2025Review
- Cardiovascular disease lipids and lipoproteins biomarker standardization.Critical reviews in clinical laboratory sciences · 2025Review
- The predictive value of TG/HDL and TC/HDL for risk of mortality and cardiovascular events in incident peritoneal dialysis patients.Clinical kidney journal · 2025Article
- Insights Into Causal Effects of Genetically Proxied Lipids and Lipid-Modifying Drug Targets on Cardiometabolic Diseases.Journal of the American Heart Association · 2025Article
- Apolipoproteins and high-density lipoprotein phospholipids as indicators of atherosclerotic cardiovascular disease in Nigeria.African journal of laboratory medicine · 2025Article
- Influence of remnant cholesterol levels on carotid intima thickness in type 2 diabetes patients.Scientific reports · 2024Article
- Effect of Adding Apolipoprotein B Testing on the Prevalence of Dyslipidemia and Risk of Cardiovascular Disease in the Korean Adult Population.Metabolites · 2024Article
- Global, regional, and national burden of ischemic stroke attributable to active smoking, 1990-2021.Tobacco induced diseases · 2024Article
- Exploring Utilization and Establishing Reference Intervals for the Apolipoprotein B Test in the Korean Population.Diagnostics (Basel, Switzerland) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
One fifth of the world population live in East Asia comprising Japan, Korea, and China where ischemic heart disease, a major component of atherosclerotic cardiovascular disease (ASCVD), is the second most frequent cause of death. Each of low-density lipoproteins (LDL), remnant lipoproteins, and lipoprotein(a), summarized as non-high-density lipoproteins (non-HDL) or apolipoprotein B (apoB) containing lipoproteins, causes ASCVD. However, a significant proportion of the evidence on lipoproteins and lipoprotein cholesterol with risk of ASCVD came from White people mainly living in Europe and North America and not from people living in East Asia or of East Asian descent. With a unique biological, geohistorical, and social background in this world region, East Asians have distinctive characteristics that might have potential impact on the association of lipoproteins and lipoprotein cholesterol with risk of ASCVD. Considering the movement across national borders in the World, understanding of lipoprotein and lipoprotein cholesterol evidence on ASCVD in East Asia is important for both East Asian and non-East Asian populations wherever they live in the World.In this review, we introduce the biological features of lipoproteins and lipoprotein cholesterol and the evidence for their association with risk of ASCVD in East Asian and European populations. We also provide an overview of guideline recommendations for prevention of ASCVD in these two different world regions. Finally, specific preventive strategies and future perspectives are touched upon.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.